Q&A | April 9, 2012

5 Challenges CROs And Big Pharma Must Address

Lathbury2

A Q&A With David Lathbury, Ph.D., VP of Chemical Development, AMRI

Contract Research Organizations (CRO) have expanded their payroll by 122% in the past 10 years, accounting for 72,000 jobs in the United States and overseas, according to a study released by the Association of Clinical Research Organizations (ACRO). In fact, the research showed that, in 2010, CROs conducted more than 11,500 clinical trials, contributed to the development of all of the top 20 prescription drugs, and in that year, oversaw research an average of 300 developmental therapies for diseases like breast cancer, diabetes, and Alzheimer's. With pharmaceutical manufacturers' continued dependence on CROs — along with the growth of global life sciences industry — challenges are bound to arise. For more on the current status of the big pharma-CRO relationship, we turned to David Lathbury of global contract research and manufacturing organization AMRI.

For full access to this content, please Register or Sign In.

Access Content 5 Challenges CROs And Big Pharma Must Address